MET-097i: Side Effects

Safety Overview#

MET-097i demonstrated acceptable tolerability in the VESPER clinical program. Gastrointestinal adverse events were the most common, consistent with the GLP-1 agonist class. The biased agonism profile (preferential G-protein signaling over beta-arrestin) may contribute to improved GI tolerability, though this has not been confirmed in head-to-head comparisons.

Biased Agonism and Tolerability#

The G-protein-biased signaling of MET-097i may reduce receptor internalization and potentially decrease the frequency of nausea and vomiting compared to balanced GLP-1 agonists. This is a theoretical advantage based on the signaling pharmacology; clinical confirmation requires larger comparative trials.

Ultra-Long Half-Life Considerations#

The approximately 380-hour half-life introduces unique safety considerations. Side effects cannot be rapidly reversed by discontinuation, as drug levels persist for weeks after the last dose. This is an important consideration for managing adverse events and in clinical situations requiring rapid drug washout.

GLP-1 Agonist Class Warnings#

Standard class warnings apply: thyroid C-cell tumors (rodent data), pancreatitis, gallbladder events, and acute kidney injury from volume depletion.

Limitations#

Safety data are limited to Phase 1/2b trials with 28-week follow-up. The immunogenicity profile of the HALO peptide-oligomer conjugate has not been fully characterized. Long-term safety data are not available.

Safety Profile Context#

MET-097i belongs to the Metabolic category of research peptides. Understanding the side effect profile of MET-097i is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of MET-097i. Side effect severity and frequency are based on available clinical data.

Nausea#

Severity: mild | Frequency: common

Most common adverse event, consistent with GLP-1 receptor agonist class. Biased agonism may result in lower rates compared to balanced GLP-1 agonists, though head-to-head data are not yet available.

Vomiting#

Severity: mild | Frequency: uncommon

Reported in clinical trials. Predominantly mild to moderate severity.

Decreased appetite#

Severity: mild | Frequency: common

Expected pharmacological effect of GLP-1 receptor activation. Contributes to weight loss efficacy.

Injection site reactions#

Severity: mild | Frequency: uncommon

Mild reactions at the subcutaneous injection site. The HALO conjugate may form a subcutaneous depot at the injection site.

Contraindications#

The following contraindications have been identified for MET-097i based on available research and pharmacological considerations:

• Investigational compound: not approved for clinical use
• Expected class contraindications based on GLP-1 receptor agonist class including personal or family history of medullary thyroid carcinoma or MEN2 syndrome

Individuals with any of these conditions should not use MET-097i without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for MET-097i:

• Drug interactions not fully characterized. GLP-1 receptor activation delays gastric emptying, potentially affecting oral drug absorption. The ultra-long half-life means drug interaction effects could persist for weeks after discontinuation.

Drug interaction studies for MET-097i remain limited. Researchers should exercise caution when combining MET-097i with other compounds and consult relevant pharmacological references.

Related Reading#

• MET-097i overview and research guide
• MET-097i dosing protocols
• MET-097i risks and legal status